Research peptides
PE-22-28
PE-22-28 is a peptide of seven amino acids made as a trimmed-down version of spadin, a 17-residue peptide that comes from the propeptide of sortilin, also known as neurotensin receptor 3. The same research group later began calling it mini-spadin.
- Container
- Glass vial, crimp seal, flip-top cap
- Storage
- -20 °C, desiccated
- Paperwork
- Lot certificate (HPLC + mass spec) shown before you pay
Lot certificates
You’ll see American Peptides on the lab’s copy. They’re our supplier.
- 10 mg, lot PE2228-0528: 99.90% purity (RP-HPLC), 10.21 mg measured, identity confirmed by mass spec. Issued 2026-06-17 by Bioviridian Inc.. Verify certificate COA4859
Our vials are filled from lots made by our supplier, American Peptides, and tested by Bioviridian Inc.The laboratory’s original certificate lists American Peptides as the vendor. Look up the code at bioviridians.com to check it.
What researchers study it for
- Pharmacology of the TREK-1 potassium channel
- Depression-related behavior tests in mice
- Neuron formation and synapse building in the hippocampus
- Stroke and depression after stroke in mice
How it is thought to work
The idea is that it blocks TREK-1, a two-pore-domain potassium channel. Patch-clamp recordings from cells carrying human TREK-1 gave an IC50 of 0.12 nM for PE-22-28, compared with 40 to 60 nM for spadin. The group later reported a two-sided action: channel activity went up at low concentrations and down at higher ones.
Where the research stands
Preclinical only. All published data come from cells and mice studied by one French laboratory. ClinicalTrials.gov lists no human trial, and the peptide is not an approved medicine.
Sources
- Mazella J, et al. (2010). Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design. PLoS Biology.
- Djillani A, et al. (2017). Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Frontiers in Pharmacology.
- Mazella J, et al. (2018). The Involvement of Sortilin/NTSR3 in Depression as the Progenitor of Spadin and Its Role in the Membrane Expression of TREK-1. Frontiers in Pharmacology.
- Pietri M, et al. (2019). First evidence of protective effects on stroke recovery and post-stroke depression induced by sortilin-derived peptides. Neuropharmacology.
For laboratory research use only. Not a drug, food, supplement or cosmetic; not for human or veterinary use. Nothing on this page is medical advice or a usage guide.